Liwei Wang

5.0k total citations · 1 hit paper
112 papers, 3.9k citations indexed

About

Liwei Wang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Liwei Wang has authored 112 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 36 papers in Molecular Biology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Liwei Wang's work include Pancreatic and Hepatic Oncology Research (20 papers), Gastric Cancer Management and Outcomes (11 papers) and Colorectal Cancer Treatments and Studies (11 papers). Liwei Wang is often cited by papers focused on Pancreatic and Hepatic Oncology Research (20 papers), Gastric Cancer Management and Outcomes (11 papers) and Colorectal Cancer Treatments and Studies (11 papers). Liwei Wang collaborates with scholars based in China, United States and Spain. Liwei Wang's co-authors include Keping Xie, Daoyan Wei, Xiangdong Le, Suyun Huang, Weihua Jiang, Jiao Feng, Jiujie Cui, Hai Hu, Weiyi Huang and Ziliang Jin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Liwei Wang

108 papers receiving 3.8k citations

Hit Papers

Regorafenib plus best supportive care versus placebo plus... 2015 2026 2018 2022 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 553 citations Yuxian Bai, Liwei Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liwei Wang China 32 2.0k 1.9k 825 778 494 112 3.9k
Paola Ulivi Italy 34 1.7k 0.9× 1.5k 0.8× 1.4k 1.6× 1.3k 1.7× 484 1.0× 182 3.7k
Yang Lü United States 35 1.9k 0.9× 1.9k 1.0× 906 1.1× 971 1.2× 308 0.6× 171 4.5k
Adrian M. Jubb United Kingdom 32 1.6k 0.8× 2.5k 1.3× 1.0k 1.2× 630 0.8× 367 0.7× 50 4.0k
Hiroyuki Uetake Japan 36 2.4k 1.2× 2.1k 1.1× 1.4k 1.6× 1.0k 1.3× 899 1.8× 200 4.9k
Zhongwu Li China 30 1.7k 0.8× 1.2k 0.6× 683 0.8× 969 1.2× 359 0.7× 177 3.4k
Naoyoshi Onoda Japan 34 1.8k 0.9× 1.3k 0.7× 866 1.0× 899 1.2× 554 1.1× 236 4.3k
Jing Yi United States 21 3.2k 1.6× 1.2k 0.6× 648 0.8× 1.7k 2.2× 437 0.9× 34 5.1k
Armand de Gramont France 28 1.8k 0.9× 1.3k 0.7× 475 0.6× 708 0.9× 371 0.8× 110 3.2k
Shunchang Jiao China 30 1.9k 0.9× 1.1k 0.6× 655 0.8× 977 1.3× 229 0.5× 144 3.4k
Rachel Midgley United Kingdom 26 1.7k 0.8× 929 0.5× 559 0.7× 440 0.6× 671 1.4× 56 2.8k

Countries citing papers authored by Liwei Wang

Since Specialization
Citations

This map shows the geographic impact of Liwei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Wang more than expected).

Fields of papers citing papers by Liwei Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liwei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Wang. The network helps show where Liwei Wang may publish in the future.

Co-authorship network of co-authors of Liwei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Liwei Wang. A scholar is included among the top collaborators of Liwei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liwei Wang. Liwei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Liwei, Gang Zhao, & Bhushan Sandeep. (2023). A review regarding the article ‘systematic review and meta-analysis of levothyroxine effect on blood pressure in patients with subclinical hypothyroidism’. Current Problems in Cardiology. 49(2). 102351–102351. 1 indexed citations
2.
Wang, Di, Liwei Wang, Liming Zheng, et al.. (2023). Enhancing the Management of Metastatic Tumors by Robust Co‐Delivery of 5‐Fluorouracil/MicroRNA‐10b Inhibitor Using EGFR‐Targeted Nanovehicles. Advanced Healthcare Materials. 12(15). e2202989–e2202989. 7 indexed citations
3.
4.
Wang, Yajing, Lulu Yang, Hao Liu, et al.. (2022). Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients. Cancer Medicine. 12(6). 7140–7148. 10 indexed citations
5.
Ge, Weiyu, Kexuan Wang, Tiebo Mao, et al.. (2022). Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Frontiers in Cell and Developmental Biology. 10. 942225–942225. 6 indexed citations
6.
Wang, Liwei, Feng Wang, Xindao Yin, et al.. (2019). Value of 68Ga-PSMA-11 PET/CT SUVmax combined with MRI ADC in the diagnosis of prostate cancer. 39(5). 257–261. 1 indexed citations
7.
Luo, Yang, Wěi Li, Zefei Jiang, et al.. (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anti-Cancer Drugs. 30(8). 866–872. 3 indexed citations
8.
Hu, Hai, Junjie Hang, Ting Han, et al.. (2016). The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumor Biology. 37(7). 8657–8664. 140 indexed citations
9.
10.
Song, Weifeng, Qi Li, Lei Wang, Weiyi Huang, & Liwei Wang. (2015). FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Scientific Reports. 5(1). 10081–10081. 20 indexed citations
11.
Kong, Xiangyu, Lei Li, Zhaoshen Li, et al.. (2013). Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer. Cancer Research. 73(13). 3987–3996. 86 indexed citations
12.
Shen, Xuxia, Yunyi Kong, Bo Dai, et al.. (2013). [Cutaneous regressing/regressed malignant melanoma: a clinicopathologic analysis of 8 cases].. PubMed. 42(10). 675–8. 1 indexed citations
13.
Ma, Jingjing, Ling Tian, Jin Cheng, et al.. (2013). Sonic Hedgehog Signaling Pathway Supports Cancer Cell Growth during Cancer Radiotherapy. PLoS ONE. 8(6). e65032–e65032. 26 indexed citations
14.
Cui, Jiujie, Weihua Jiang, Shu‐Yi Wang, Liwei Wang, & Keping Xie. (2012). Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer. Current Pharmaceutical Design. 18(17). 2464–2471. 121 indexed citations
15.
Huang, Chen, Zhengjun Qiu, Liwei Wang, et al.. (2011). A Novel FoxM1-Caveolin Signaling Pathway Promotes Pancreatic Cancer Invasion and Metastasis. Cancer Research. 72(3). 655–665. 147 indexed citations
16.
Gao, Yong, Zhiliang Jia, Xiangyu Kong, et al.. (2011). Combining Betulinic Acid and Mithramycin A Effectively Suppresses Pancreatic Cancer by Inhibiting Proliferation, Invasion, and Angiogenesis. Cancer Research. 71(15). 5182–5193. 85 indexed citations
17.
Jia, Zhiliang, Yong Gao, Liwei Wang, et al.. (2010). Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity. Cancer Research. 70(3). 1111–1119. 63 indexed citations
18.
Wang, Liwei. (2010). Retrospective investigation of 65 cases with multiple primary cancers. 4 indexed citations
19.
Wang, Liwei. (2010). The measurement of serum cystatin C for renal function of patients with malignant tumors. Tumori. 1 indexed citations
20.
Zhang, Jinchao, Liwei Wang, Dandan Liu, et al.. (2010). Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development. Anti-Cancer Agents in Medicinal Chemistry. 10(4). 272–282. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Ulivi Breakdown of academic impact, for papers by Yang Lü Breakdown of academic impact, for papers by Adrian M. Jubb Breakdown of academic impact, for papers by Hiroyuki Uetake Breakdown of academic impact, for papers by Zhongwu Li Breakdown of academic impact, for papers by Naoyoshi Onoda Breakdown of academic impact, for papers by Jing Yi Breakdown of academic impact, for papers by Armand de Gramont Breakdown of academic impact, for papers by Shunchang Jiao Breakdown of academic impact, for papers by Rachel Midgley
Rankless by CCL
2026